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A new role of the brain natriuretic peptide in the heart: modulation
of cardiac precursor cell proliferation and differentiation.
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The actual role of the brain natriuretic peptide (BNP) in the heart remains
elusive despite its reported protective effect in ischemic animal hearts.
Because recently BNP was shown to control the proliferation and differentia-
tion of murine embryonic stem cells, we asked in this study whether BNP
could influence the proliferation and differentiation of cardiac progenitor cells
(CPC) in vitro and in vivo. We first identified a c-kit+ Sca-1+ cell population
present in neonatal and adult hearts which expressed the NPR-A and NPR-B
receptors. In vitro, these cells proliferated and in presence of BNP differenti-
ated into CPCs (c-kit+ Sca-1+ Nkx2.5+) and into mature cardiomyocytes. In
parallel, BNP was injected to newborn and adult healthy mice (n=6 mice per
group). In the hearts of both neonatal and adult mice, BNP injection increased
the number of newly formed cardiomyocytes (neonatal: + 23%, p= 0.009 and
adult: +68%, p= 0.005) and the number of CPCs (neonatal: + 142%, p= 0.002
and adult: +134%, p= 0.04). BrdU injection to neonatal BNP treated mice
demonstrated that BNP stimulated CPC proliferation. In anticipation that BNP
might be used as a therapeutic agent, we injected BNP into mice undergoing
myocardial infarction (n=6-7 mice per group). Higher numbers of Nkx2.5+
cells were detected in both the infarcted (+38%, p=0.03) and non infarcted
areas (+69%, p=0.02) of BNP treated hearts one week after surgery. Finally,
by isolating neonatal cardiac cells from the hearts of NPR-A or NPR-B defi-
cient mice, we demonstrated that BNP modulates the fate of CPCs via NPR-
B binding and that long term BNP treatment is correlated in vitro and in vivo
with decreased Protein Kinase G activity. Our results highlight a new key role
for BNP in the control of CPC proliferation and/or differentiation. This new
function of BNP should be evaluated in therapies aimed to induce cardiac cell
regeneration and should reopen the debate about the therapeutic use of BNP
for patients suffering from heart diseases.
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Cardiac p11 expression is related to 5-HT4 receptor pathway in fai-
ling and non-failing rat left ventricular cardiomyocytes
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Aim: Heart failure is the inability to maintain a sufficient cardiac output
necessary to meet metabolic demand. Cellular compensatory mechanisms,
such as the serotonin 4 receptor (5-HT4R) pathway, take place to improve the
defective cardiac excitation-contraction coupling (CEC). However, little is
known about the regulation of this pathway. Our objective was to investigate
the potential involvement of the 5-HT4R partner p11 in the activation of the
pathway during heart failure.
Methods and results: Wistar rats underwent ligation of the left coronary
artery to mimic infarction. Control Sham-operated animals underwent the
same surgery without ligation. Seven weeks post myocardial infarction (PMI)
hearts were collected and/or enzymatically digested in order to perform bio-
chemical studies or to assess intracellular calcium (Ca2+) handling at the single
cell level. p11 mRNA expression in the left posterior wall was significantly
increased at 7 weeks PMI compared to Sham (272±40 vs.141±27 A.U,
P<0.05). However, p11 protein levels in 7 weeks PMI myocytes showed a
trend toward a decrease compared to sham (0,16±0,02 vs. 0,25±0,09). Inter-
estingly, the expression of the p11 partner Annexin A2 was significantly
increased (1,52±0.32 vs. 0,53±0.14, P<0.05) suggesting improved p11 sta-
bility. At the CEC level, stimulation of the 5-HT4R pathway by prucalopride
did not exert an effect on all CEC parameters evaluated in both PMI and Sham
myocytes. Nevertheless, induction of p11 expression by Brain-Derived
Neuron Factor treatment in freshly isolated healthy myocytes showed a
remarkable increase in Ca2+ transient amplitude (0,27±0,02 vs. 0,18±0,01,
P<0.05) and basal Ca2+level (0,67±0,01 vs. 0,64±0,01, P<0.05) following
prucalopride stimulation compared to untreated cells.
Conclusion: Cardiac expression of p11 seems to play a role in the modu-
lation of the response to 5-HT4R pathway in both failing and non-failing
hearts.
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Role of epac signalling in doxorubicin-induced cardiotoxicity
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The canonical mechanisms underlying doxorubicin (Dox)-induced cardio-
toxicity involve Reactive Oxygen Species production, DNA intercalation and
topoisomerase II inhibition which trigger DNA damage, oxidative stress and
alteration of calcium homeostasis leading to myocyte death and heart dysfunc-
tion. However, alternative mechanisms with prior or concomitant dox induced
alteration of signalling pathways are emerging. β-adrenergic signalling and
especially Epac (exchange protein directly activated by cAMP) could be worth
investigating as Epac activate small G proteins Rac1 and Rho A known to be
implicated in dox-induced cardiotoxicity. We investigated the time/dose-
dependent Dox effect in in vitro (neonatal rat cardiomyocytes) and in vivo on
a mice models on 1/ the transcriptional activity of cardiac remodelling
markers (ANF, SRE and SkM α-actin) 2/ Epac’s downstream effectors (small
G proteins expression, MEF-2,NFAT) and 3/ Epac’s role in dox-induced DNA
damage. In vitro, Dox treatment resulted in an alteration of Epac signalling
through inhibition of stress and remodelling markers, a modulation of Epac’s
downstream effectors and a direct effect of Dox on Epac1 and Epac2 expres-
sion. Moreover, the protein level of DNA damage marker (H2AX pS139) was
modulated by Epac1 and 2 inhibitors and by Epac2 inhibitor which suggest a
new protective pathway through Epac1 specific inhibition. In vivo, echocar-
diography of Dox-treated mice (3 iv injections, 12mg/kg total dose) showed a
dilated cardiomyopathy from 15 weeks. At the molecular level, we observed
a statistically significant Epac1, Epac2, Rho A and Rac1 expression modula-
tion between 6 and 20 weeks suggesting a time-dependent regulation of Epac
signalling in Dox-induced cardiotoxicity. Our results indicate for the first time
an integrated time-course of Dox induced-alteration in Epac signalling, and a
potential role of Epac in myocyte death induced by Dox.
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ShcA is an adaptor protein that binds to tyrosine kinase receptors. Its germ
line deletion is embryonic lethal with abnormal cardiovascular system forma-
tion. We used the Cre-loxP technology and the smooth muscle protein-22
(Sm22) cre transgene, to ablate ShcA specifically in the cardiovascular system
from early embryonic development. Conditionally mutant mice developed
signs of severe dilated cardiomyopathy, myocardial infarctions, and premature
death. No evidence of a vascular contribution to the phenotype was observed.
Histological analysis of the heart reveals aberrant intercalated z-disk and M-
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band structures, and misalignments of T-tubules with z-disk. We find that the
neuregulin-1-ErbB3 signaling and the baroreceptor reflex response, which
have been functionally associated, are both altered in the mutant mice. We fur-
ther demonstrate that ShcA interacts with Cav-1 and the costameric protein
plasma membrane Ca2+/calmodulin-dependent ATPase (PMCA), and that its
deletion leads to abnormal dystrophin signaling. Our studies demonstrate that
ShcA modulates ErbB3/Neuregulin and Cav-1/dystrophin signaling, two cru-
cial pathways for z-disk and costamere linkages in cardiomyocytes.
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Gevokizumab, an IL1-beta modulating antibody exerts promising
cardioprotective effects against ischemia-reperfusion injury in diabe-
tic rats.
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Aims: Enhanced myocardial interleukin-1 beta (IL1-β) production is
involved in ischemia/reperfusion (I/R) induced left ventricular (LV) dysfunc-
tion. We tested neutralization of IL-1β as a potential therapeutic target for the
treatment of I/R induced LV dysfunction.
Methods: We assessed in diabetic (Goto Kakizaki, GK) rats the preventive
effects of gevokizumab, a potent modulator of IL-1β, administered once a
week, started 4 weeks prior to a 20 min of transient ischemia induced by left
coronary artery occlusion and continued 90 days after I/R, on LV remodeling/
function (echocardiography) 7 and 90 days after I/R. LV hemodynamics (LV
catheterization), LV tissue perfusion (MRI) and LV collagen density (image
analysis) were assessed 90 days after I/R.
Results: I/R induced early LV expansion followed by late LV dilatation,
associated with LV dysfunction as well as after 90 days, reduced LV tissue per-
fusion and LV collagen accumulation. Gevokizumab limited both early LV
expansion as well as late LV dilatation, associated with an improved LV func-
tion. Ninety days after I/R, gevokizumab improved both LV systolic and LV dia-
stolic functions, illustrated by the increase in LV end-systolic pressure volume
relation, and the reductions in LV end-diastolic pressure and LV end-diastolic
pressure volume relation. Moreover, long-term gevokizumab moderately
increased LV tissue perfusion and significantly reduced LV collagen density.
Conclusions: Our results, obtained using a clinically relevant model of I/R,
suggest a therapeutic benefit of the IL-1β modulating antibody, gevokizumab, in
myocardial I/R injury.
LVDD: left ventricular diastolic diameters; LVFS:LV fractional short-
ening; LVESPVR and LVEDPVR: LV end-diastolic and end-systolic pressure
volume relations. *:p<0.05 vs GK; † p<0.05 vs GK I/R
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Early and delayed IL-1 beta antibody gevokizumab treatments pre-
vent cardiac remodeling and reverse coronary endothelial dysfunction
following myocardial infarction injury in Goto Kakizaki rats
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Aims: Cardiac interleukin-1 beta (IL1-β) production is enhanced acutely
after myocardial infarction and is involved in myocardial damages. We tested
if early and delayed IL1-β modulations by IL-1β antibody, gevokizumab, pre-
vent left ventricular (LV) remodeling and endothelial dysfunction induced by
LV ischemia/reperfusion (I/R) in diabetic rats.
Methods: Gevokizumab (Gevo; 10 mg/kg) was administered 1 hour
(early) or 7 days (delayed) following reperfusion, after a 20 min of transient
ischemia induced by LV artery occlusion and continued every week for
90 days. Delayed perindopril (1 mg/kg) was used as a positive control. LV
remodeling and function were assessed (Echocardiography) at 7 and 90 days.
LV hemodynamics (Millar catheterization) and relaxation of isolated coronary
arteries to acetylcholine (Mulvany wiregraph) were evaluated at 90 days.
Collagen density and leukocytes infiltration were evaluated (Histology) at
90 days.
Results: At 7 days, early Gevo limited the early LV expansion and reduc-
tion of FS induced by I/R. At 90 days both of early and delayed Gevo as well
as perindopril limited in a similar manner, the LV late dilatation, the reduction
of FS and LV systolic and diastolic dysfunction induced by I/R. At 90 days,
GK coronary endothelium-dependent relaxation to acetylcholine was impaired
by I/R (59±13 vs.17±4%, p<0.05). Early, delayed Gevo and perindopril
restored the (86±4, 92±2 and 98±1% respectively; p<0.05 vs GK+I/R) coro-
nary relaxation to acetylcholine. Early, delayed Gevo and perindopril signifi-
cantly reduced collagen density and leukocytes infiltration at 90 days.
Conclusions: In a clinically relevant model of acute myocardial infarction,
the IL-1β antibody gevokizumab started early or late after myocardial reper-
fusion exerts immediate and late cardiovascular protection.
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